Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant

BACKGROUND: Measles, mumps, and rubella (MMR) vaccine is a live-attenuated vaccine usually contraindicated within the first 2 years of hematopoietic cell transplant (HCT). The objective of this study was to assess the safety of MMR vaccine when administered within 2 years of HCT. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Desjardins, Michaël, Mitre, Xhoi, Sherman, Amy C, Walsh, Stephen R, Cheng, Matthew P, Kanjilal, Sanjat, Ho, Vincent T, Baden, Lindsey R, Issa, Nicolas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664685/
https://www.ncbi.nlm.nih.gov/pubmed/34909436
http://dx.doi.org/10.1093/ofid/ofab504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664685/
https://www.ncbi.nlm.nih.gov/pubmed/34909436
http://dx.doi.org/10.1093/ofid/ofab504

Ejemplares similares